Last reviewed · How we verify
NaF PET-CT
At a glance
| Generic name | NaF PET-CT |
|---|---|
| Sponsor | Atlantic Health System |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (PHASE2)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging
- Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy (PHASE1)
- Imaging in MGUS, SMM and MM (PHASE2)
- 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer (PHASE2)
- A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones (PHASE2)
- Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaF PET-CT CI brief — competitive landscape report
- NaF PET-CT updates RSS · CI watch RSS
- Atlantic Health System portfolio CI